Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fennec Pharmaceuticals Inc. - Common Stock (NQ:FENC)

6.265 -0.235 (-3.62%)
Streaming Delayed Price Updated: 12:56 PM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fennec Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Expert Ratings for Fennec Pharmaceuticals ↗
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Fennec Pharmaceuticals ↗
 
Via Benzinga
News headline image
4 Analysts Have This to Say About Fennec Pharmaceuticals ↗
 
Via Benzinga
Where Fennec Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
After Two FDA Rejections, Fennec Pharma Lead Drug Scores US Approval For Chemo-Induced Hearing Loss ↗
 
Via Benzinga
News headline image
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
News headline image
NASDAQ:FENC Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Fennec Pharmaceuticals Inc. ↗
San Diego, CA -- (SBWIRE) -- 06/01/2022 -- Certain directors of Fennec Pharmaceuticals Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
News headline image
U.S. FDA accepts Fennec Pharma's New Drug Application (NDA) Resubmission for PEDMARK ↗
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) announced that the U.S. 
Via Benzinga
News headline image
NASDAQ:FENC Shareholder Notice: Deadline on April 11, 2022 in Lawsuit Against Fennec Pharmaceuticals Inc. ↗
San Diego, CA -- (SBWIRE) -- 04/11/2022 -- A deadline is coming up on April 11, 2022 in the lawsuit filed for certain investors of Fennec Pharmaceuticals Inc. (NASDAQ:FENC). 
Via SBWire
News headline image
FENC Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and Last Few Hours to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
FENC FINAL DEADLINE APRIL 11: NATIONALLY RANKED ROSEN LAW FIRM Encourages Fennec Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Monday Deadline in Securities Class Action - FENC
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pharmaceuticals Inc. (FENC)
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Fennec Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FENC
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Fennec Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FENC
WHY: NEW YORK, NY - (NewMediaWire) - March 11, 2022 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of... 
Via NewMediaWire
Topics Lawsuit
News headline image
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Fennec Pharmaceuticals Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - FENC
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Investor Notice: Lawsuit Alleges Violations of Securities Laws ↗
San Diego, CA -- (SBWIRE) -- 02/24/2022 -- An investor, who purchased NASDAQ:FENC shares, filed a lawsuit against Fennec Pharmaceuticals Inc. over alleged violations of Federal Securities Laws. 
Via SBWire
News headline image
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pharmaceuticals Inc. (FENC)
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Kirby McInerney LLP Investors That a Class Action Lawsuit Has Been Filed on Behalf of Fennec Pharmaceuticals Inc. (FENC) Investors and Encourages Investors to Contact the Firm Before April 11, 2022
From Kirby McInerney LLP
Via Business Wire
News headline image
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pharmaceuticals Inc. (FENC)
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fennec Pharmaceuticals Inc. (FENC) Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fennec Pharmaceuticals Inc. (FENC) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Fennec Pharmaceuticals Inc. (FENC) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Shareholder Alert: Robbins LLP Reminds Investors That Fennec Pharmaceuticals Inc. (FENC) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
News headline image
ROSEN, A LEADING LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action FENC
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
FENNEC ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Fennec Pharmaceuticals Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fennec Pharmaceuticals Inc. (FENC) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.